TW200716595A - Chromane and chromene derivatives and uses thereof - Google Patents

Chromane and chromene derivatives and uses thereof

Info

Publication number
TW200716595A
TW200716595A TW095114313A TW95114313A TW200716595A TW 200716595 A TW200716595 A TW 200716595A TW 095114313 A TW095114313 A TW 095114313A TW 95114313 A TW95114313 A TW 95114313A TW 200716595 A TW200716595 A TW 200716595A
Authority
TW
Taiwan
Prior art keywords
compounds
chromane
chromene derivatives
agonists
subclasses
Prior art date
Application number
TW095114313A
Other languages
English (en)
Chinese (zh)
Inventor
Gavin David Heffernan
Gary Paul Stack
Jonathan Laird Gross
da-hui Zhou
Hong Gao
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of TW200716595A publication Critical patent/TW200716595A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
TW095114313A 2005-04-22 2006-04-21 Chromane and chromene derivatives and uses thereof TW200716595A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67382005P 2005-04-22 2005-04-22

Publications (1)

Publication Number Publication Date
TW200716595A true TW200716595A (en) 2007-05-01

Family

ID=36888961

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095114313A TW200716595A (en) 2005-04-22 2006-04-21 Chromane and chromene derivatives and uses thereof

Country Status (19)

Country Link
US (2) US7365095B2 (US20060258714A1-20061116-C00111.png)
EP (1) EP1874756A1 (US20060258714A1-20061116-C00111.png)
JP (1) JP2008538576A (US20060258714A1-20061116-C00111.png)
KR (1) KR20080008378A (US20060258714A1-20061116-C00111.png)
CN (1) CN101203505A (US20060258714A1-20061116-C00111.png)
AR (1) AR056320A1 (US20060258714A1-20061116-C00111.png)
AU (1) AU2006239937A1 (US20060258714A1-20061116-C00111.png)
BR (1) BRPI0610027A2 (US20060258714A1-20061116-C00111.png)
CA (1) CA2605587A1 (US20060258714A1-20061116-C00111.png)
CO (1) CO6321153A2 (US20060258714A1-20061116-C00111.png)
GT (1) GT200600166A (US20060258714A1-20061116-C00111.png)
IL (1) IL186837A0 (US20060258714A1-20061116-C00111.png)
MX (1) MX2007013163A (US20060258714A1-20061116-C00111.png)
NO (1) NO20075641L (US20060258714A1-20061116-C00111.png)
PE (1) PE20061297A1 (US20060258714A1-20061116-C00111.png)
RU (1) RU2007139541A (US20060258714A1-20061116-C00111.png)
TW (1) TW200716595A (US20060258714A1-20061116-C00111.png)
WO (1) WO2006116165A1 (US20060258714A1-20061116-C00111.png)
ZA (1) ZA200709052B (US20060258714A1-20061116-C00111.png)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
PE20061298A1 (es) * 2005-04-22 2006-12-24 Wyeth Corp Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
JP2008538575A (ja) * 2005-04-22 2008-10-30 ワイス ベンゾジオキサンおよびベンゾジオキソラン誘導体ならびにそれらの使用
AU2006239900A1 (en) * 2005-04-22 2006-11-02 Wyeth Therapeutic combinations for the treatment or prevention of psychotic disorders
CA2605554A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
AR056320A1 (es) * 2005-04-22 2007-10-03 Wyeth Corp Derivados de cromano y cromeno, procesos de obtencion, composiciones farmaceuticas y usos de los mismos
CN101203216A (zh) * 2005-04-22 2008-06-18 惠氏公司 二氢苯并呋喃衍生物及其用途
WO2006116149A1 (en) * 2005-04-22 2006-11-02 Wyeth New therapeutic combianations for the treatment or prevention of depression
MX2007013065A (es) * 2005-04-22 2008-01-14 Wyeth Corp Derivados de dihidrobenzofurano y usos de los mismos.
GT200600160A (es) * 2005-04-22 2007-03-14 Tratamiento del dolor
EP1874292A2 (en) * 2005-04-24 2008-01-09 Wyeth Methods for modulating bladder function
PE20080172A1 (es) * 2006-03-24 2008-04-21 Wyeth Corp Compuestos dihidrobenzofuranil alcanamida como moduladores del receptor 5-ht2c
TW200815388A (en) * 2006-04-18 2008-04-01 Wyeth Corp Chromane and chromene derivatives and uses thereof
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
CL2007003043A1 (es) * 2006-10-24 2008-05-30 Wyeth Corp Compuestos derivados de cromano; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y ansiedad entre otros.
WO2008052088A1 (en) * 2006-10-25 2008-05-02 Wyeth Chromane derivatives, synthesis thereof, and intermediates thereto
EP2197532A1 (en) 2007-08-06 2010-06-23 Serenity Pharmaceuticals Corporation Methods and devices for desmopressin drug delivery
WO2009063992A1 (ja) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
US8914112B2 (en) 2008-01-23 2014-12-16 Boston Scienctific Neuromodulation Corporation Methods and systems of treating pancreatitis pain caused by sphincter of Oddi dysfunction
US8676322B2 (en) 2008-01-30 2014-03-18 Boston Scientific Neuromodulation Corporation Methods and systems of treating pancreatitis pain
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
NO2296686T3 (US20060258714A1-20061116-C00111.png) 2008-05-21 2014-07-12
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
CN101921252B (zh) * 2010-07-02 2012-05-09 中国科学院上海有机化学研究所 1-氧杂苯并杂环类化合物、合成方法和用途
MX344516B (es) 2010-12-21 2016-12-19 Colgate Palmolive Co Bifenoles halogenados como agentes antibacterianos.
CN104854068A (zh) * 2012-12-18 2015-08-19 帝斯曼知识产权资产管理有限公司 由(r)-6,10-14-三甲基十五碳-5-烯-2-酮制备的(6r,10r)-6,10,14-三甲基十五烷-2-酮
KR101592560B1 (ko) * 2013-06-21 2016-02-05 제주대학교 산학협력단 신규 플라보노이드 및 그 용도
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
JP6657241B2 (ja) 2015-02-11 2020-03-04 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． Ｃｎｓ疾患を治療するための１−複素環イソクロマニル化合物およびアナログ
AU2017301767A1 (en) 2016-07-29 2019-02-14 Pgi Drug Discovery Llc Compounds and compositions and uses thereof
CN116514761A (zh) 2016-07-29 2023-08-01 赛诺维信制药公司 化合物、组合物及其用途
AU2018312559B2 (en) 2017-08-02 2022-06-02 Pgi Drug Discovery Llc Isochroman compounds and uses thereof
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
AU2020223284A1 (en) * 2019-02-17 2021-09-16 Neurawell Therapeutics Compositions and methods for treatment of depression and other disorders
EP3938045A1 (en) 2019-03-14 2022-01-19 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1262078A (en) 1968-05-24 1972-02-02 Fisons Pharmaceuticals Ltd Preparation of phenoxy fumaric acid compounds and chromone-2-carboxylic acid compounds therefrom
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4654362A (en) 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5089637A (en) 1990-03-21 1992-02-18 Pfizer Inc. Process and intermediates for 2r-benzyl-chroman-6-carbaldehyde
JP3283114B2 (ja) 1992-09-07 2002-05-20 クミアイ化学工業株式会社 縮合ヘテロ環誘導体及び農園芸用殺菌剤
US5731324A (en) 1993-07-22 1998-03-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
ATE256130T1 (de) 1993-08-19 2003-12-15 Janssen Pharmaceutica Nv Gefässverengende dihydrobenzopyranderivate
US6150402A (en) 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
DE4430089A1 (de) 1994-08-25 1996-02-29 Bayer Ag Verfahren zur enzymatischen Herstellung von enantiomerenreinen Chroman-2-carbonsäuren und deren Derivaten
SI0707007T1 (en) 1994-10-14 2002-04-30 Merck Patent Gmbh (R)-(-)-2-(5-(4-fluorophenyl)-3-pyridylmethylaminomethyl)chromane as CNS active agent
US5658796A (en) 1995-06-07 1997-08-19 Seprachem, Inc. Optical resolution of alkyl chroman-2-carboxylates
EP0971878B1 (en) 1997-02-27 2008-03-26 Takeda Pharmaceutical Company Limited Amine compounds, their production and use as amyloid-beta production inhibitors
FR2763335B1 (fr) 1997-05-16 2000-11-24 Adir Nouveaux composes heterocycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6133277A (en) 1997-12-05 2000-10-17 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
US20060258176A1 (en) * 1998-02-05 2006-11-16 Asm Japan K.K. Method for forming insulation film
US6011035A (en) * 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
FR2791675B1 (fr) 1999-03-30 2001-05-04 Synthelabo Derives de n-[2-(4-aminophenyl) ethyl] -2,3-dihydro-1,4- benzodioxinne-2-methanamine, leur preparation et leur application en therapeutique
DE10044091A1 (de) 2000-09-07 2002-04-04 Merck Patent Gmbh Chromanonderivate
US20040029788A1 (en) 2000-11-01 2004-02-12 Hans-Markus Bender Methods and compositions for the treatment of diseases of the eye
DE10120619A1 (de) 2001-04-26 2002-10-31 Merck Patent Gmbh 2-(5-(4-Fluorphenyl)-3-pyridylmethylaminomethyl-chroman
BR0211604A (pt) 2001-08-01 2004-08-24 Merck Patent Gmbh Inibidores de integrina para o tratamento de doenças do olho
CN1561338A (zh) 2001-10-04 2005-01-05 惠氏公司 作为5－羟基色胺－6配体的苯并二氢吡喃衍生物
WO2003029239A1 (en) 2001-10-04 2003-04-10 Wyeth Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands
WO2003031439A1 (en) 2001-10-05 2003-04-17 Wyeth Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1h-indole
CN1564818A (zh) 2001-10-05 2005-01-12 惠氏公司 2－羟甲基－苯并二氢吡喃的立体选择性合成方法
CA2462860A1 (en) 2001-10-05 2003-04-17 Wyeth Stereospecific process for the synthesis of 2-yl chroman derivatives
US20050014818A1 (en) 2001-11-09 2005-01-20 Masaru Mitsuda Process for producing optically active chroman derivative and intermediate
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
WO2004045534A2 (en) 2002-11-15 2004-06-03 Galileo Pharmaceuticals, Inc. Chroman derivatives for the reduction of inflammation symptoms
CA2580584C (en) 2003-09-19 2015-07-28 Galileo Pharmaceuticals, Inc. Use of alpha-tocotrienol for treatment of mitochondrial diseases
DE10348257A1 (de) 2003-10-16 2005-05-25 Merck Patent Gmbh Verfahren zur Herstellung von enantiomereneinen in 2-Position substituierten Chromanderivaten
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7728155B2 (en) * 2003-10-24 2010-06-01 Wyeth Llc Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
DE102004011265A1 (de) 2004-03-09 2005-09-29 Lutz F. Prof. Dr. Tietze Synthese von Vitamin E
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
WO2006065484A2 (en) 2004-11-24 2006-06-22 Abbott Laboratories Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof
CN101203216A (zh) * 2005-04-22 2008-06-18 惠氏公司 二氢苯并呋喃衍生物及其用途
MX2007013065A (es) * 2005-04-22 2008-01-14 Wyeth Corp Derivados de dihidrobenzofurano y usos de los mismos.
CA2605554A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
JP2008538766A (ja) * 2005-04-22 2008-11-06 ワイス 薬物乱用の処置
AU2006239900A1 (en) * 2005-04-22 2006-11-02 Wyeth Therapeutic combinations for the treatment or prevention of psychotic disorders
JP2008538575A (ja) * 2005-04-22 2008-10-30 ワイス ベンゾジオキサンおよびベンゾジオキソラン誘導体ならびにそれらの使用
WO2006116149A1 (en) * 2005-04-22 2006-11-02 Wyeth New therapeutic combianations for the treatment or prevention of depression
GT200600160A (es) * 2005-04-22 2007-03-14 Tratamiento del dolor
AR056320A1 (es) * 2005-04-22 2007-10-03 Wyeth Corp Derivados de cromano y cromeno, procesos de obtencion, composiciones farmaceuticas y usos de los mismos
GT200600158A (es) * 2005-04-22 2006-11-28 Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina
EP1874292A2 (en) * 2005-04-24 2008-01-09 Wyeth Methods for modulating bladder function

Also Published As

Publication number Publication date
US20080182891A1 (en) 2008-07-31
RU2007139541A (ru) 2009-05-27
BRPI0610027A2 (pt) 2010-05-18
US20060258714A1 (en) 2006-11-16
CO6321153A2 (es) 2011-09-20
EP1874756A1 (en) 2008-01-09
AR056320A1 (es) 2007-10-03
GT200600166A (es) 2007-03-14
ZA200709052B (en) 2009-08-26
JP2008538576A (ja) 2008-10-30
KR20080008378A (ko) 2008-01-23
PE20061297A1 (es) 2006-12-24
US7365095B2 (en) 2008-04-29
NO20075641L (no) 2007-11-20
MX2007013163A (es) 2008-01-21
WO2006116165A1 (en) 2006-11-02
IL186837A0 (en) 2008-02-09
CA2605587A1 (en) 2006-11-02
CN101203505A (zh) 2008-06-18
AU2006239937A1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
TW200716595A (en) Chromane and chromene derivatives and uses thereof
TW200720266A (en) Benzodioxane and benzodioxolan derivatives and uses thereof
MX2007013021A (es) Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
TW200718692A (en) Dihydrobenzofuran derivatives and uses thereof
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
WO2006050007A3 (en) Substituted indolizines and derivatives as cns agents
BRPI0415657A (pt) derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
GEP20125538B (en) 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases
TW200716584A (en) Dihydrobenzofuran derivatives and uses thereof
WO2007140439A3 (en) Compounds as cannabinoid receptor ligands and uses thereof
MX2009011205A (es) Derivados de 2-iminoisotiazol como ligandos del receptor canabinoide.
TW200730511A (en) Chroman compounds
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
AR049276A1 (es) Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen
TW200800962A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
PL1831152T3 (pl) Pochodne tetraliny i indanu oraz ich zastosowanie jako antagonistów 5-HT
TW200740795A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
PL1831191T3 (pl) Pochodne chromanu i ich zastosowanie jako ligandów receptorów 5-HT
TW200730510A (en) Chroman compounds
WO2008052075A3 (en) Benzoxazine derivatives and uses thereof
WO2008052088A8 (en) Chromane derivatives, synthesis thereof, and intermediates thereto
WO2007123941A3 (en) Chromane and chromene derivatives and uses thereof
WO2008052078A3 (en) Benzoxathiine and benzoxathiole derivatives and uses thereof
PT1893589E (pt) Derivados substituídos de n-benzo[d]isoxazol-3-il-amina como inibidores de recetores mglur5, recetores de serotonina-(5-ht) e recetores de noradrenalina e sua utilização na produção de medicamentos